% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • dpemco dpemco Jul 18, 2012 2:29 PM Flag

    rating update from Needham

    Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); Q2 Preview of Adcetris Sales
    1:06 PM ET, 07/18/2012 - Street Insider

    Needham & Company maintains a 'Buy' on Seattle Genetics (NASDAQ: SGEN).

    Analyst, Alan Carr, said, "SGEN is expected to report 2Q12 financial results on 8/8/12. Our 2Q12 Adcetris net sales estimate is $36.3M. The company reported $34.5M in 1Q12 Adcetris sales (+4% q/q). Volume growth was +12% q/q. Management provided initial 2012 Adcetris sales guidance of $140-150M in May 2012."

    "We are focused on the long-term commercial potential of Adcetris. Data from three ongoing company-sponsored Adcetris clinical trials were presented at the ASCO meeting in early June. Results from a Phase 2 retreatment trial indicate physicians can return to the drug and expect efficacy comparable to initial treatment. Encouraging signs of efficacy were seen in the first interim analysis of a Phase 2 trial in CD30+ r/r NHL patients, including r/r DLBCL (4/7 OR)...An MAA for Adcetris was accepted by the EMA in June 2011. We expect approval in Europe in 2H12, at which point a milestone payment from Takeda is due."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
39.97+0.55(+1.40%)May 24 4:00 PMEDT